DXCM Stock Analysis: Buy, Sell, or Hold?
DXCM - DexCom, Inc.
$61.63
3.81 (6.59%)
▲
5d:
+1.68%
30d:
+0.65%
90d:
-11.98%
BUY
HIGH Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: Apr 30, 2026
0d
Smart Money Distribution
DXCM is up 4.9% this week, but smart money is buying puts. Top strike: $70 2026-06-18 with 5,212 OI. Put ratio: 62% View Scanner →
Strength: 3.6/10
Get Alerted When DXCM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
3 traders called DXCM this week
80% bullish • 2 bearish
80% bullish • 2 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: DXCM appears deeply undervalued. Market expects -6.1% annual earnings decline despite 92% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: DXCM appears deeply undervalued. Market expects -6.1% annual earnings decline despite 92% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$125.33
Based on 11.1% avg growth
INTRINSIC VALUE TODAY
$77.82
20.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 24.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: DXCM is currently trading at $61.63, which is considered fair relative to its 30-day fair value range of $59.51 to $63.74. From a valuation perspective, the stock is trading at a discount (Forward PE: 20.2) compared to its historical average (24.4). Remarkably, the market is currently pricing in an annual earnings decline of 6.1% over the next few years. This pessimistic expectation contrasts with the company's recent 92.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, DXCM is in a strong downtrend. The price is approaching resistance at $63.19. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.6% recently.
Market Sentiment: DXCM has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $83.28 (+35.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DXCM is in a strong downtrend. The price is approaching resistance at $63.19. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.6% recently.
Market Sentiment: DXCM has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $83.28 (+35.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$59.51 -
$63.74
Company Quality Score
66/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
88.1%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.6%)
- BULLISH: Trading 35.1% below Wall St target ($83.28)
Trading Range Analysis
30-Day Trading Range
$59.51 -
$63.74
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$57.66
Resistance Level
$63.19
Current Trend
Strong Downtrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
20.21
Wall Street Target
$83.28
(+35.1%)
Revenue Growth (YoY)
15.0%
Earnings Growth (YoY)
92.2%
Profit Margin
19.3%
Valuation Discount vs History
-6.1% cheaper
PE vs Historical
20.2 vs 24.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-6.1%
(market-implied from PE analysis)
1-Year Target
$57.87
(-6%)
2-Year Target
$54.34
(-12%)
3-Year Target
$51.03
(-17%)
3-Yr Target (if PE normalizes)
(PE: 20→24)
$61.62
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.1, Growth: 18.2%)
$111.21
(+81%)
Base:
(SPY PE: 20.2, Growth: 18.2%)
$101.82
(+65%)
Bear:
(PE: 17.2, Growth: 18.2%)
$86.54
(+40%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (25x PE), but valuation improves significantly next year (20x PE) as earnings recover.
Trailing PE: 24.82 | Current EPS (TTM): $2.33
Bull Case
$83.26
(+35%)
Analyst growth 30.9%, PE expands to 27.3
Base Case
$75.69
(+23%)
Market implied 30.9%, PE stable at 24.8
Bear Case
$39.32
(-36%)
Severe decline -20.0%, PE contracts to 21.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 20.2 to 24.4
Stabilization Target:
$74.42
(+20.8%)
PE Expansion Potential:
+20.8%
Share & Embed Analysis
Last updated: May 18, 2026 7:28 AM ET
Data refreshes hourly during market hours. Next update: 8:28 AM
Data refreshes hourly during market hours. Next update: 8:28 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DXCM showing a specific setup today?
Insider Activity (6 Months)
3
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Michael Jon Brown
SELL
1700 shares
2026-04-15
Ro Khanna
SELL
2026-03-30
Ro Khanna
SELL
2026-03-23
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$85 | 59 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$389 | 58 HOLD |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$119 | 55 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
23 analysts |
$250 | 59 HOLD |
|
ZBH
Zimmer Biomet Holdings I… |
HOLD
29 analysts |
$99 | 62 BUY |
Advanced DXCM Option Strategies
Professional options setups generated by AI based on today's DXCM price and gamma walls.
